Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies

Guy Biber1,4, Aviad Ben-Shmuel1,4, Elad Noy1, Noah Joseph1, Abhishek Puthenveetil1, Neria Reiss1, Omer Levy1, Itay Lazar1, Ariel Feiglin1, Yanay Ofran1, Meirav Kedmi1,2,3, Abraham Avigdor2,3, Sophia Fried1 & Mira Barda-Saad1

Cancer cells depend on actin cytoskeleton rearrangement to carry out hallmark malignant functions including activation, proliferation, migration and invasiveness. Wiskott–Aldrich Syndrome protein (WASp) is an actin nucleation-promoting factor and is a key regulator of actin polymerization in hematopoietic cells. The involvement of WASp in malignancies is incompletely understood. Since WASp is exclusively expressed in hematopoietic cells, we performed in silico screening to identify small molecule compounds (SMCs) that bind WASp and promote its degradation. We describe here one such identified molecule; this WASp-targeting SMC inhibits key WASp-dependent actin processes in several types of hematopoietic malignancies in vitro and in vivo without affecting naïve healthy cells. This small molecule demonstrates limited toxicity and immunogenic effects, and thus, might serve as an effective strategy to treat specific hematopoietic malignancies in a safe and precisely targeted manner.

1 The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel. 2 Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel. 3 Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 4 These authors contributed equally: Guy Biber, Aviad Ben-Shmuel. ✉email: Mira.Barda-Saad@biu.ac.il
Hematopoietic malignancies are a leading cause of cancer incidence and death, with an estimated 690,000 deaths and 1,186,590 new cases worldwide in 2018. Hematopoietic malignancies are a heterogeneous collection of lymphoproliferative or myeloproliferative diseases, which can develop in the bone marrow, blood, lymph nodes, and lymphatic or non-lymphatic organs. These types of malignancies are mainly characterized by uncontrolled cellular proliferation, enhanced motility, and invasiveness into adjacent or distal tissues, allowing cells to spread and invade other tissues in the body. In this study, we focused on the common lymphoproliferative hematopoietic malignancies, leukemia and Non-Hodgkin’s lymphoma (NHL). Hematopoietic malignancies accounted for ~10% of all cancer-associated deaths in 2018, with NHL and leukemia as the leading hematological cancers.

Current treatments for hematopoietic malignancies are still based mainly on chemotherapy and radiotherapy, and are usually followed by hematopoietic stem cell transplantation in cases of leukemia. These treatments are nonspecific and accompanied by severe side effects including sensitivity to infections, hair loss, chronic fatigue, heart disorders, infertility, and secondary cancers. Immune-based therapies, such as monoclonal antibodies, bispecific antibodies, immune checkpoint inhibitors, immunomodulators, and adoptive cell transfer (ACT), have shown significant clinical benefits, although many patients still fail to respond to these treatments due to primary, adaptive, and acquired resistance. In the case of checkpoint inhibitors, treatment with Nivolumab (anti-PD-1) showed promising clinical results for Hodgkin’s lymphoma patients but low complete response rates for NHL patients. Furthermore, modest results were obtained using a combination treatment with anti-CTLA-4 and anti-PD-1 antibodies. In addition, treatments with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cells in patients with relapsed acute lymphoblastic leukemia (ALL) or refractory B-cell lymphomas showed limited success. Although these new immune-based treatments might help to minimize the severe side effects of chemotherapy and radiotherapy, there are many reports of patients who still develop severe side effects from damage to healthy bystander cells, renal damage, cytokine release syndrome, and graft-versus-host disease (GVHD). Therefore, the development of new drugs to treat hematopoietic malignancies with minimal side effects and higher efficacy is still a critical unmet need.

Hematopoietic malignancies are varied in terms of the origin of the neoplastic cells, and are genetically diverse due to random mutations and chromosomal translocation events resulting from viral infections or genome instability. The formation of neoplasms is a multistep process in which the cells acquire biological capabilities known as hallmarks of cancer, that ultimately transform them into malignant cells. The cytoskeleton, and in particular the actin-network, are vital in order to carry out these newly acquired enhanced cellular capabilities. These hallmarks of cancer enable malignant cells to become autonomously activated, to independently and uncontrollably proliferate, and to increasingly migrate, invade, and metastasize to adjacent and distant tissues. These activities are defined as actin-dependent processes.

Wiskott–Aldrich Syndrome protein (WASP) belongs to a family of actin nucleation-promoting factors (NPFs) that regulate actin-cytoskeleton network rearrangement by activating the actin-related protein 2/3 (Arp2/3) complex. WASP is exclusively expressed in hematopoietic cells, and thus has a unique role in their cellular activities. This vital role of WASP can be seen in patients with Wiskott–Aldrich Syndrome (WAS) or X-linked thrombocytopenia (XLT). WAS patients exhibit a broad range of immune deficiencies due to the absence or decrease in WASP expression, respectively. Although WASP itself has a pivotal role in healthy hematopoietic cell function, its function in malignant hematopoietic cells is still unclear. Other WAS homologs from the WASp NPF family of proteins, such as Neural Wiskott–Aldrich Syndrome protein (N-WASP), were found to be verprolin homologous proteins (WAVE) 1–3, Wiskott–Aldrich syndrome protein and SCAR homologue (WASH), WASH homolog associated with actin, membranes and microtubules (WHAMM), and junction mediating regulatory protein (JMY), are ubiquitously expressed in most healthy cell types, and have a well described role in various types of cancers as key players in mediating molecular pathways.

In our previous studies, we established the molecular mechanism regulating WASp degradation. Following cellular activation, WASP undergoes ubiquitination on lysine residues 76 and 81, located at the WASp homology I (WH1) domain, directing WASp to proteosomal degradation. Furthermore, we demonstrated that WASp-interacting protein (WIP) masks WASP ubiquitination sites at the WH1 domain, thereby protecting it from degradation. Upon cellular activation, WASP is recruited to the membrane, and is activated by the small G-protein, Cdc42, which binds to its GTPase-binding domain (GBD); concurrently, WASP is phosphorylated on tyrosine 291. This activation releases WASP from its auto-inhibitory state and results in a partial dissociation from the C-terminus of WIP at the N-terminal WH1 domain of WASp, while retaining its interaction between the C terminus of WASp and the N-terminus of WIP. As a result, WASP is subsequently degraded by the Cbl E3 ubiquitin ligase. Due to the constant activation of cancer cells, and the induction of WASp activity, which serves as a key regulator of actin-dependent processes including cellular proliferation, migration, and invasiveness, WASP may play a critical role in mediating these hallmarks of cancer. Of note, WAS patients exhibit deficiencies in all hematopoietic cellular compartments. Thus, although the role of WASp in cancer remains enigmatic, it might serve as an attractive target for treatment of a wide range of hematopoietic malignancies in a selective manner, relative to healthy nonactivated hematopoietic cells.

Here, we performed in silico screening using a machine learning trained predictor to identify SMCs that may interfere with the WIP-WASp interaction at the WH1 domain, thereby exposing WASp to degradation. Out of dozens of high score predicted molecules, the SMC, 8-(2,3-dihydro-1H-inden-2-yl)-1-isobutyl-3-(4-methoxybenzyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione, termed WASp-targeting SMC #13 was selected. We show that this agent specifically binds WASp and not its homologs, induces its degradation, and inhibits key cellular WASp-dependent processes including activation, proliferation, migration, and invasiveness of multiple types of malignant hematopoietic cells, without affecting nonhematopoietic or naïve hematopoietic populations. Furthermore, we demonstrate that this WASp-targeting SMC abolishes the growth of human NHL in an in vivo mouse model.

Results
In silico screening for WASp-binding SMCs. In order to identify possible SMCs that can bind to WASp and disrupt its interaction with WIP, we performed machine learning-enhanced virtual screening of drug-like candidate compounds (Supplementary Fig. 1a).

Since the structural model of the WASp WH1 domain is currently unavailable, a surrogate model was created by using the published NMR model of a recombinant WH1 domain of N-WASP, stabilized via a linker fragment and fusion to a short WIP peptide (PDB ID: 2IFS). Since N-WASP is the closest homolog...
Leading SMC-WASp putative binding pairs were selected. Results molecules predicted as most likely to bind to the protein, least likely to bind to the given protein, and a score of 1 indicating (with a score of 0 signifying a small molecule predicted to be the pairs that occur and those that do not. Using the same entitating docking models that are representative of protein-SMC algorithm (as described in Materials and Methods)47,48. were generated for each drug-like compound using the Small Molecule Repository. Up to 10 different 3D conformations were generated for each drug-like compound using the ‘FAST’ algorithm (as described in Materials and Methods)47,48.

Putative binding was evaluated for each conformational model of every drug-like SMC candidate with the surrogate WASp model. First, docking was performed via PatchDock (parameters are specified in the Materials & Methods section)49,50. Then the interaction was scored using a machine learning-based classifier. Briefly, the classifier used was trained to distinguish between protein-small molecules pairs that bind each other and pairs that do not, based on docking results. The docking models were each transformed into a numerical representation (i.e., a feature vector) based on the characteristics of the putative protein-ligand model of each pair. By contrasting known protein-SMC pairs (positively labeled samples) with random pairing of SMC and proteins (assumed not to occur, thus labeled as negative examples), the classifier was trained using differentiating docking models that are representative of protein-SMC pairs that occur and those that do not. Using the same docking model to feature vector pipeline in conjunction with the trained classifier, putative binding pairs were similarly scored (with a score of 0 signifying a small molecule predicted to be the least likely to bind to the given protein, and a score of 1 indicating molecules predicted as most likely to bind to the protein). Leading SMC-WASp putative binding pairs were selected. Results were further filtered by discarding any structure with a putative binding site that is not in close (>5 Å) proximity to the WASp degradation site, comprising lysine residues 76 and 81. The leading drug-like molecules were further evaluated using Dreiding-like forcefield structural optimization51 to redock52 the candidates and the protein. Virtual screening showed that out of dozens of high score predicted molecules, the SMC, 8-(2,3-dihydro-1H-inden-2-yl)-1-isobutyl-3-(4-methoxybenzyl)-1,3,8-triazaspiro[4.5]decan-2,4-dione (Supplementary Fig. 1b), termed WASP-targeting SMC #13, had the required properties, and was selected for further characterization of specificity and biological relevance. We performed an analysis of drug-likeness potential using the SwissADME online tool53 and characterized the physicochemical properties of SMC #13 (Table 1). Based on the

| Table 1 Characterization the physiochemical properties of SMC #13 and drug-likeness potential using the SwissADME online tool. |
|---------------------------------------------------------------|
| **Parameters**                                              |
| Molecular weight                                           | 461.6 g/mol |
| No. of H bond acceptors                                     | 4          |
| No. of H bond donors                                        | 0          |
| Topological polar surface area (TPSA)                       | 53.09 Å    |
| Partition coefficient—Log P                                 | 3.78       |
| Solubility—Log S                                            | −5.44      |
| GI absorption                                              | High       |
| BBB permeant                                                | Yes        |
| P-gp substrate                                              | No         |
| Drug likeness                                              | Yes        |
| Bioavailability score                                       | 0.55       |

GI: Gastrointestinal, BBB: brain-blood barrier, P-gp: P-glycoprotein.

of WASp, the N-WASp-WIP model was modified with the use of a virtual mutagenesis tool46 to obtain a relevant prediction for WASp.

Subsequently, this structural model was used to virtually screen a 2D structure library of ~320,000 drug-like compounds that was obtained from ChemBridge Corporation’s “CORE Library compound collection” and NIH MLSMR (Molecular Libraries Small Molecule Repository). Up to 10 different 3D conformations were generated for each drug-like compound using the ‘FAST’ algorithm (as described in Materials and Methods)47,48.

Specific binding of SMC #13 to WASp. To validate the in silico binding prediction, we confirmed the specific binding of SMC #13 to the WH1 domain of WASp in whole-cell lysates using Microscale thermophoresis (MST)54. We expressed YFP-WASP in HEK 293 T cells, which are nonhematopoietic cells and lack expression of endogenous WASp, but express WIP. Whole-cell lysates (WCL) were prepared containing wt YFP-WASP and tested for MST fluorescence quality validation. A binding curve of SMC #13 to YFP-WASp wt was determined, with an estimated Kd of 30.8 ± 13.6 nM (Fig. 1a). Furthermore, we tested the in silico predicted WASp WH1 domain binding site of SMC #13. MST analysis showed elimination of SMC #13 binding to the YFP-WASp ΔWH1 mutant, supporting the WH1 domain as the putative binding site of SMC #13 (Fig. 1b).

Biolayer interferometry (BLI) was used as an orthogonal method to validate the specific binding of SMC #13 to the WH1 domain of WASp. As can be seen in Fig. 1c, clear concentration dependent binding occurs between SMC #13 and YFP-WASp wt, while no concentration dependent binding was observed between SMC #13 and YFP-WASp ΔWH1 (Fig. 1d). In MST experiments, no binding was detected between SMC #13 and WASp homologs such as N-WASp or WAVE2 (Supplementary Fig. 2a and b, respectively). In contrast to N-WASp, WAVE2 lacks a WH1 domain42,55 and is not expected to bind SMC #13 but was used to control for the possible effect on other WASp family members. Moreover, MST analysis showed neither nonspecific binding of SMC #13 to the YFP tag (Supplementary Fig. 2c) nor irrelevant SMC binding (ROCK inhibitorY-27632) to YFP-WASP wt (Supplementary Fig. 2d). Similarly, BLI analysis demonstrated the lack of off-target binding of SMC #13 to N-WASp (Fig. 1e), WAVE2 (Fig. 1f), and the YFP tag, which was taken as a subtracted reference for the BLI experiments. All of the binding experiments were conducted following quality check using western blot analysis (Supplementary Fig. 3a). Collectively these data show that SMC #13 specifically binds WASp at the WH1 domain, and does not bind other NPF homologs, supporting the selective targeting of this compound to hematopoietic cells.

WASP-targeting SMC #13 downregulates WASp cellular levels by upregulation of its ubiquitylation. To verify the biological effect of the selected SMC, T-ALL Jurkat cells were incubated for 24 h with increasing concentrations of SMC #13. Following incubation, WASp cellular concentration levels were compared with those detected in control cells treated with equivalent concentrations of DMSO (vehicle) (Fig. 2a, Supplementary Fig. 11). Incubation of leukemic cells with various concentrations of SMC #13 resulted in a corresponding downregulation of WASp in a dose-dependent manner relative to the control (Fig. 2a, Supplementary Fig. 11). At 40 µM SMC #13, the WASp cellular concentration was markedly reduced after 24 h incubation, and thus we chose this concentration for our further in vitro experiments.

We next examined whether this reduction of WASp levels stems from its enhanced ubiquitylation and consequent degradation. T-ALL cells were incubated with SMC #13, followed by treatment with the proteasome inhibitor, MG132. Cells were lysed, and the whole-cell lysates were immunoprecipitated with anti-WASP antibody and immunoblotted with anti-ubiquitin or
**Fig. 1 Binding of SMC #13 to WASp detected by MST and BLI analyses.** MST: Diluted cell lysates of a YFP-WASp wt ($n = 5$), and b YFP- WASp ΔWH1 ($n = 5$) from HEK 293 T cells were incubated with serially diluted (1.5 nM–200 μM) SMC #13. The mixed lysates and SMC were then loaded into standard-treated Monolith™ capillaries, and the fluorescence of the samples was measured at 50% blue LED power in the Monolith NT.115 instrument at high MST power. Binding curves were generated by NanoTemper Analysis 2.2.31 software, and the normalized fluorescence is plotted as a function of SMC concentration. The calculated Kd is 30.8 ± 13.6 nM. Data shown as an average ± SD. BLI biolayer interferometry measurements using super streptavidin biosensors with biotinylated GFP antibody showing the binding of SMC #13 to c YFP-WASp wt, d YFP-WASp ΔWH1, e N-WASp- YFP, or f YFP-WAVE2. The specific binding of the indicated proteins was analyzed with serially diluted SMC #13 (50–200 μM).
anti-WASp antibodies. As predicted, treatment with SMC #13 almost completely abrogated cellular WASp. However, treatment of the cells with MG132 inhibited WASp degradation and restored ubiquitylated WASp levels (Fig. 2b, Supplementary Fig. 11). These results are consistent with SMC-dependent degradation of WASp through enhanced ubiquitylation and proteasomal-dependent degradation.

WIP binds WASp and protects its degradation sites from ubiquitylation. Thus, we assessed by fluorescence resonance energy transfer (FRET) whether the enhanced ubiquitylation of WASp following incubation with SMC #13 was the direct consequence of interference with the WIP-WASp interaction. T-ALL Jurkat cells expressing CFP-WASp and YFP-WIP were...
plated on stimulatory coverslips coated with anti-CD3 antibody, and were then fixed after 2 min of activation. Close association between WIP and WASp is expected to enable high FRET efficiency due to the proximity of CFP by the CFP emission spectrum. In the control-treated cells, clustering of WIP and WASp occurred with an average FRET efficiency of 37.7 ± 3.1%, while the FRET efficiency between CFP-WASP and YFP-WIP in the WASp-deficient Jurkat cell line (Jurkat WASp KO). KO cells were transfected with either YFP-WASP wt or YFP-WASP ΔWH1. Cells were treated with 40 μM of SM1 #13 or DMSO vehicle (control). Incubation with SM1 #13 resulted in a reduction of YFP-WASP cellular concentration but not that of YFP-WASP ΔWH1 (Fig. 2d, Supplementary Fig. 11). This result further validates the specificity of SM1 #13 for the WASp WH1 domain, which regulates WASp degradation. Moreover, to confirm that WASp degradation is not influenced by induced changes in actin-cytoskeleton polymerization, we incubated Jurkat cells with either SM1 #13 or the actin depolymerizing drug, cytochalasin D. Treatment with Cytochalasin D or DMSO (negative control) had no observable effect on WASp stability, whereas a clear reduction in WASp level was observed in cells treated with SM1 #13 (Supplementary Fig. 3b). To further confirm the effect of SM1 #13 on WASp degradation, we analyzed the mRNA expression level of WASp by qPCR and normalized to GAPDH expression. As a result of inside-out signaling, which is mainly dependent on low to the intermediate binding affinity conformation of LFA-1 as well as integrins activation66,73. We therefore examined the functional consequences of WASp downregulation by SM1 #13 on cellular activation, as demonstrated by the affinity maturation of LFA-1 (lymphocyte function-associated antigen 1)74–77. Malignant hematopoietic cells are often constitutively activated75. Primary T cells obtained from WAS patients or WAS-deficient mice is severely decreased65. Thus, we tested the effect of WASp degradation by SM1 #13 on the proliferation of cancerous cells using the XTT proliferation assay. Treatment with SM1 #13 significantly decreased the proliferation of treated T-ALL cells by 40 ± 8% relative to cells treated with vehicle, control (P ≤ 0.05) (Fig. 2f).

Studies using cells from WAS patients or mouse models have shown that WASp is a key regulator of actin-dependent processes, including cell activation, migration, and invasiveness66–70. Primary T cells obtained from WAS patients have impaired activation when stimulated with anti-CD3 mAb24,71,72, and integrin activation66,73. We therefore examined the functional consequences of WASp downregulation by SM1 #13 on cellular activation, as demonstrated by the affinity maturation of LFA-1 (lymphocyte function-associated antigen 1)74–77. Malignant hematopoietic cells are often constitutively activated23. This activation is evident by the transition from the low to the intermediate binding affinity conformation of LFA-1 as a result of inside-out signaling8, which is mainly dependent on F-actin binding to adaptor proteins in the cell membrane, e.g., vinculin or talin79,80. The intermediate and high affinity conformations of LFA-1 are recognized by the KIM127 antibody81,82. T-ALL cells were treated with SM1 #13 (red curve) and analyzed for KIM127 staining using flow cytometry in vehicle for 12 h. After this pretreatment, cells were also incubated with CHX, and WASp cellular concentration was measured over 8 h (Fig. 2e, Supplementary Fig. 11). In the vehicle-treated cells (neg. cont.) WASp levels were relatively stable, with a noticeable reduction only after 8 h of incubation with CHX. In contrast, in SM1 #13-treated cells, WASp was more rapidly degraded and significantly decreased after the first 4 h. WASp levels were reduced following 4, 6, and 8 h by 43.2 ± 12.3% (P ≤ 0.04), 50.9 ± 10.5% (P ≤ 0.02), and 75.7 ± 4.3% (P ≤ 0.008), respectively. These data demonstrate that SM1 #13 downregulates WASp expression on the protein level by a mechanism of enhanced degradation.
comparison to vehicle-treated cells (blue curve). Treatment with SMC #13 dramatically decreased LFA-1 affinity maturation by 62.6 ± 9.9% (P ≤ 0.01) (Fig. 2g, Supplementary Fig. 12a).

WASp-dependent migration is downregulated in hematopoietic cells following SMC #13 treatment. As mentioned above, WASp is a key factor supporting the directional migration of hematopoietic cells33,70,83. To determine the effect of SMC #13 on migration, malignant primary CLL cells and primary NHL cells from marginal B-cell lymphoma patients were obtained from recently diagnosed, untreated patients. Lymphocytes were isolated from the blood samples, and incubated with SMC #13, or with the vehicle as a negative control. WASp cellular concentration was determined by western blot in primary CLL cells (Fig. 3a, Supplementary Fig. 11) and primary NHL cells (Fig. 3b, Supplementary Fig. 11) relative to the vehicle control. SMC #13 caused a reduction of 60 ± 10.9% (P ≤ 0.0032) and 54 ± 12% (P ≤ 0.005) in WASp cellular concentration in primary CLL and NHL cells, respectively. Lymphoma cells are characterized by high migratory capacity, which facilitates their distribution to distant tissues34. Since WASp is a key player in cellular motility, we examined whether treatment with WASp-targeting SMC attenuates the migration of primary CLL and NHL cells. The cells were seeded over slides precoated with ICAM-1 and SDF-1α55,65. Movement of the cells was automatically tracked and analyzed following treatment with SMC #1387. Strikingly, a significant inhibition of cellular migration was observed in SMC #13-treated primary CLL cells, which migrated to a distance of 23.4 ± 4.4 μm, compared to control cells, which migrated to a distance of 75.7 ± 6.7 μm (P ≤ 0.0001) (Fig. 3c and movies S1-S2). This effect was also evident in primary marginal B-cell lymphoma cells, wherein treatment with SMC #13 significantly decreased cellular motility to 24 ± 2.5 μm relative to the control cells, which migrated a distance of 48.1 ± 2.6 μm (P ≤ 0.0001) (Fig. 3d and Supplementary movies 3-4). These results were also corroborated using migration analysis of T-ALL expressing WASp wt or WASp KO cells to ensure the on-target effect of SMC #13. As seen in Fig. S3E, WASp KO cells exhibit a heavily reduced cell displacement similar to the well described phenotype of WAS patient cells and similar to SMC13 treatment39. Since WASp is exclusively expressed in hematopoietic cells, we verified that SMC #13 does not affect other WASp family proteins (e.g., N-WASp and WAVEs) in bystander nonhematopoietic cells. Therefore, we used scratch-wound assay to demonstrate that SMC #13 does not have any effect on the migration of the nonhematopoietic melanoma cells, MEL1106. As can be seen in supplementary Fig. 4, while cytochalasin D inhibited cell migration, SMC #13 did not have any effect on cell movement relative to the vehicle-treated cells (Supplementary Fig. 4a-c).

SMC #13 does not affect naïve healthy primary cells. Since disassociation occurs between the C-terminal region of WIP and the N-terminal region of WASp, leading to the exposure of WASp degradation sites40, it is likely that this disassociation upon activation is necessary to enable the binding of SMC #13. SMC#13 binding may thus affect the equilibrium of the WIP-WASp complex and skew it in favor of the unbound open conformation. To examine this possibility, we determined whether SMC #13 selectively affects activated hematopoietic cells, including malignant cells. For this purpose, PBMCs were isolated from the blood of healthy donors46. The PBMCs were either left untreated or were activated with PMA and ionomycin. Both naïve and activated cells were treated either with SMC #13 or with vehicle. The cellular concentration of WASp was evaluated using western blot. The normalized WASp levels of the naïve and activated SMC #13-treated cells were calculated relative to vehicle-treated cells (Fig. 4a, Supplementary Fig. 11). Downregulation of WASp levels (72.8 ± 7.3%) was observed only in activated SMC #13-treated PBMCs but not in naïve PBMCs obtained from healthy donors (P ≤ 0.04).

To further investigate the effect of SMC #13 on naïve vs. activated PBMCs, we determined the proliferative capacity of these cells using an XTT-based proliferation assay. To this end, PBMCs were isolated from blood samples of healthy donors and were left inactivated, or activated with PMA and ionomycin, following treatment with SMC #13 or vehicle as control (Fig. 4b). Naïve PBMCs that were treated with SMC #13 did not show any significant change in proliferation. Upon activation, the proliferation rate of the PBMCs increased by 33.2 ± 5.2% relative to the naïve cells (P ≤ 0.02). Strikingly, when activated PBMCs were incubated with SMC #13, their proliferation decreased by 73 ± 10.2% relative to the activated vehicle-treated PBMCs (P ≤ 0.01). These data clearly suggest that SMC #13 selectively affects activated cells.

Next, we examined whether SMC #13 affects the migration of freshly isolated PBMCs from healthy donors. The cells were activated with PMA and ionomycin or left inactivated, followed by treatment with SMC #13 or vehicle. Remarkably, naïve PBMCs did not exhibit any significant change in their chemotaxis displacement when treated with SMC #13 versus vehicle. However, when the cells were preactivated and treated with SMC #13, their directional migration was impaired and their cell displacement was significantly decreased, to a distance of 36.4 ± 2.7 μm relative to untreated activated cells, which migrated to a distance of 76.1 ± 3.2 μm (P ≤ 0.00004), (Fig. 4c and Supplementary movies 5-8). Collectively, these results demonstrate that SMC #13 affects only activated PBMCs. Furthermore, activated PBMCs treated with vehicle showed significantly higher WASp levels, which may be correlated with higher WASp-dependent cellular activity in malignant cells, in analogy to other WASp homologs e.g., N-WASP and WAVE58,89.

SMC #13 lacks cytotoxic side effects. To evaluate the potential safety of SMC #13, we examined the median toxic dose (TD50) of SMC #13 by measuring cell viability using the propidium iodide (PI) assay (Supplementary Fig. 5). Freshly isolated PBMCs from a healthy donor were incubated with increasing concentrations of SMC #13 ranging from 18.75 to 600 μM. After incubation with SMC #13 for 24 h, the cell viability was determined relative to the negative control-treated cells. Using a linear trend line formula, the TD50 was calculated as 171 μM.

Next, we evaluated the potential of SMC #13 to induce hemolysis. At the lowest tested concentration, 0.3125 mM of SMC #13, which is 7.8-fold higher than the concentrations we used in the in vitro assays (40 µM), a minor and insignificant level (0.7 ± 0.07%) of hemolysis was detected. Even at the maximal concentration of 5 mM, which is 125-fold higher than the in vitro concentration (40 µM) only 21.9 ± 1.1% hemolysis was observed (Supplementary Fig. 6a).

We further investigated the possible propensity of SMC#13 to provoke an immune response and cytokine secretion. Following incubation of SMC #13 with PBMCs from healthy donors, the secretion of key human inflammatory cytokines including IL-6, IL-10, TNF-α, and IFN-γ was determined using an ELISA-based cytokine assay. The concentrations of these inflammatory cytokines were not significantly different between SMC #13 incubated cells and the negative controls (Supplementary Fig. 6b). These findings demonstrate that the immune system is largely unaffected by SMC #13, and that this agent does not induce cytokine release.

The safety of systemic SMC #13 administration in vivo. To determine the suitability of SMC #13 as a lead compound for
**Fig. 3** Downregulation of WASp cellular concentration by SMC #13 affects primary cancer cell activities. **a** Effect on WASp levels: Primary CLL cells \((P = 0.0320)\) or **b** primary NHL cells were incubated with 40 \(\mu\)M SMC #13 or vehicle for 24 h \((P = 0.0469)\). Cells were lysed, and analyzed by immunoblot with anti-WASp and anti-GAPDH as a loading control. Densitometric analysis of the bands was performed with ImageJ, and is presented below the blots. Relative WASp levels were normalized to GAPDH and compared to the control. Values are shown as mean ± SEM of three independent experiments. The \(p\) values were calculated using two-tailed paired \(t\)-test.

**c, d** Migration assay following incubation with 40 \(\mu\)M SMC #13 in **c** primary CLL \((P < 0.0001)\), or **d** primary NHL cells \((P < 0.0001)\). Following 24 h incubation, cells were seeded on a chambered coverslip precoated with ICAM-1, and the random movement of the cells was assessed using Zeiss Observer Z1 inverted microscope and automatically tracked and analyzed. Left panel: Cell tracking analysis of five cells from a representative movie of each group. Each line represents the pathway of a single cell. Right panel: Graph summarizing the mean cell displacement (Neg Cont.: \(n = 104\) CLL cells, 467 NHL cells; SMC #13 \(n = 58\) CLL cells, 541 NHL cells). Values are shown as mean ± SEM; the \(P\) value of two-tailed unpaired \(t\)-test is shown.
in vivo studies, we examined whether it induced toxic effects in mice. Diabetic/severe combined immunodeficiency (SCID/NOD) mice received a single intraperitoneal (i.p) injection either with 100 mg/kg of SMC #13 or vehicle only as a control group. There was no evidence of weight loss (Supplementary Fig. 7a), lethargy, or other physical indicators of morbidity or stress over the course of 21 days following treatment. To further examine whether SMC #13 could be tolerated as a drug used for extended treatment, we tested safety of 100 mg/kg in multiple i.p injections. (Supplementary Fig. 7b). No toxic effects or other indicators of morbidity or tissue damage to the heart, lung, liver, kidney, bowel, or spleen (macroscopic or microscopic) were detected. These studies support the safety of SMC #13 for in vivo preclinical efficacy studies.

Fig. 4 SMC #13 does not affect WASp cellular concentration and WASp-dependent cellular function in healthy naïve primary cells. a PBMCs were incubated with 40 µM SMC #13 or vehicle, and were left unstimulated, or stimulated with 1 µg/ml ionomycin and 2.5 ng/ml PMA for 24 h (P < 0.0001) and (P = 0.0140 for vehicle unstimulated vs SMC#13 stimulated)). The cells were then lysed and analyzed by immunoblot with anti-WASp antibody and anti-GAPDH as a loading control. Densitometric analysis of the bands was performed with ImageJ, and the values are presented below the blots. WASp cellular concentration levels were normalized to GAPDH and compared relative to the unstimulated vehicle-treated cells. Values are shown as mean ± SEM of three independent experiments. The P values were calculated using one-way anova and Tukey’s multiple comparison test. n.s not significant. b XTT proliferation assay was performed following 40 µM SMC #13 incubation and/or stimulation of PBMCs, as described in a. The graph summarizes the mean percent cell proliferation relative to the control (P = 0.0003 for stimulated vehicle vs SMC#13). Values are shown as mean ± SEM of three independent experiments. The P values were calculated using one-way anova and Tukey’s multiple comparison test. n.s not significant. c PBMCs were incubated with 40 µM SMC #13 or control, left unstimulated or stimulated for 24 h, and then seeded on a chambered coverslip precoated with ICAM-1. Cell migration was assessed using Zeiss Observer Z1 inverted microscope. Left panel: Cell tracking analysis of five cells from a representative movie of each group. Each line represents the pathway of a single cell. The graph on the right summarizes the mean cell displacement (Neg Cont. (−): n = 301; SMC #13 (−): n = 255; Neg Cont. (+): n = 301; SMC #13 (+): n = 264) (P < 0.0001 for Stimulated vehicle control vs SMC#13). Values are shown as mean ± SEM of three independent experiments. The P values were calculated using one-way anova and Tukey’s multiple comparison test. n.s not significant.
Durability in the plasma and pharmacokinetics of SMC #13 in vivo. We next characterized the stability and distribution of SMC #13 in vivo, by measuring the pharmacokinetics in the plasma and within the tumors of mice bearing human Burkitt’s lymphoma tumors (Raji), using High-Performance Liquid Chromatography (HPLC) for drug detection. The SCID/NOD mice were engrafted subcutaneously with Raji cells between their shoulders. Once the tumors developed and their volume reached an average of 300 mm³, the mice were injected i.p with 100 mg/kg of SMC #13. Mice were sacrificed at the indicated timepoints, and samples from both blood and tumors were analyzed (Fig. 5a and Supplementary Fig. 8). The concentrations of SMC #13 at the various timepoints are shown in Fig. 5a. Notably, the C_max in the tumor was 97.2 ± 14.5 μM at the 30 min timepoint (Fig. 5a, red curve). These data suggest that SMC #13 can be administered systemically through the bloodstream, and that it reaches the in vitro therapeutic concentration of 40 μM inside the tumor within the first 30 min.

Furthermore, we performed a plasma protein binding (PPB) assay of SMC #13, evaluating its binding to full plasma proteins and in vitro cultured media supplemented with serum. Following 30 min incubation of SMC #13 with full plasma, medium, or PBS as a control, unbound SMC was separated from the protein bound SMC #13 complex using a molecular weight cutoff of 10KD and measured using HPLC. The calculated PPB of SMC #13 was measured to be ~85.9%, while in vitro media supplemented with fetal calf serum (FCS) yielded 78% binding (Supplementary Fig. 9). Furthermore, we also predicted the PPB value of SMC#13 to be 85% using “preADMET”, a virtual predictor.

SMC #13 suppresses in vivo tumor growth of human NHL cells following systemic administration. To determine whether SMC #13 could suppress in vivo tumor growth, we determined the efficacy of SMC#13 in vivo on human NHL cells. We subcutaneously engrafted Raji cells in SCID mice. Once the tumors reached an average of ~100 mm³ in volume, mice were randomly divided into two groups to receive i.p injections of 100 mg/kg SMC #13 or vehicle only every 72 h, for a total of six injections. Tumor volume was measured daily to determine the effect of SMC #13 on tumor growth (Fig. 5b) and on the average growth rate of the tumors from the first treatment (Fig. 5c). SMC #13-treated mice showed significantly smaller tumor volumes with an average of 457.7 ± 83 mm³ and growth rate of 23.8 ± 5.3 mm³/day compared to the vehicle-treated mice that presented an average tumor volume of 1826.1 ± 233.7 mm³ and growth rate of 106.7 ± 14 mm³/day (P < 0.001 and P < 0.0001) (Fig. 5b-d). In addition, the number of cells isolated from the tumor was significantly lower in SMC #13-treated mice compared to the control group (P < 0.05) (Fig. 5e). Furthermore, treatment with SMC #13 was effective at significantly prolonging survival in tumor-bearing mice (Fig. 5f).

SMC #13 suppresses WASp-dependent cellular functions in human NHL tumor cells recovered following treatment. Ex vivo analyses of WASp cellular concentration and its regulation on NHL tumor obtained samples was performed 24 h after the last i.p injection into mice. Consistent with the previous findings, WASp levels were decreased by 46.3 ± 6.4% in cells obtained from the SMC #13-treated mice compared to the control group, as detected by western blot (P < 0.01) (Fig. 6a, Supplementary Fig. 11). Cellular proliferation of SMC #13-treated tumor cells was decreased by 80 ± 3% (P < 0.0001) relative to cells from the control-treated mice (Fig. 6b). Integrin activation was decreased by 30.8 ± 3.4% in the treated group compared with the control group (P < 0.02) (Fig. 6c, Supplementary Fig. 12b). Furthermore, systemic administration of SMC #13 led to a reduction in the ex vivo migratory capacity of the lymphoma cells, with an average displacement of 20.5 ± 2.6 μm in comparison to 80.7 ± 8.5 μm in the vehicle-treated cells (P ≤ 0.0001). Downregulation of WASp via SMC #13 resulted in an average decrease of 74.6% in the migration of B-NHL cells (Fig. 6d). Next, we determined the invasive capacity of tumor cells by measuring ECM degradation. Equal numbers of tumor cells isolated from SMC #13 and vehicle-treated mice were incubated for a period of 24 h on fluorescent gelatin. The invasive capacity was measured by gelatin degradation, and was calculated relative to the cell area as determined by F-actin staining using phalloidin. Strikingly, tumor cells from control mice degraded an average gelatin area of 92.2 ± 2.9% compared to the SMC #13-treated tumor cells, which degraded an average gelatin area of 31.5 ± 3.3% (P < 0.0001) (Fig. 6e).

To further elucidate the impact of SMC #13 on the tumor cells, we examined the expression levels of the proliferation marker Ki-67, and Caspase-3 as an apoptosis marker, using immunohistochemistry (IHC) in mouse tumor sections. Histological analysis showed a significant difference in proliferation as measured by Ki-67 staining (Fig. 6f). Ki-67 was reduced by two fold in tumor sections obtained from SMC #13-treated mice relative to the control mice. The tumor sections were stained with an antibody that recognizes the active cleaved form of Caspase-3 to detect apoptotic cells. We observed a significant increase of ~2.45 ± 0.01 fold in apoptotic cells in sections from SMC #13-treated mice relative to control xenografts (Fig. 6g).

Taken together, our data demonstrate that SMC #13 specifically binds to the key regulator of the actin-cytoskeleton, WASp, enhances its degradation, and downregulates actin-based processes including integrin activation, cellular proliferation, migration, and invasiveness. This study demonstrates that this WASp-targeting SMC has powerful suppressive effects on human leukemia/lymphoma cells and could potentially warrant translation towards testing in clinical trials.

**Discussion**

Current treatments for certain types of hematopoietic malignancies have significantly improved overall survival (e.g., ALL, aggressive NHL), while available treatments for others (e.g., AML) are far from adequate. Furthermore, considerable challenges remain with standard chemotherapy, including lack of specificity, high toxicity, and multiple side effects. Therefore, new treatment strategies are required to improve efficacy and reduce current drawbacks either as alternative monotherapies or combinatorial treatments.

To date, the role of WASp in malignant cells is poorly understood in comparison to the well-known properties of its homologs N-WASp and WAVE in non-hematopoietic cells. In this study, we leveraged the natural mechanism of WASp ubiquitination and degradation as a strategy to specifically target hematopoietic cancer cells. The critical role of WASp as a key regulator of the actin cytoskeleton is well documented in WAS/XLT patients. Cells obtained from these patients exhibit poor activation, proliferation, and migration capabilities. These actin-dependent processes are hallmarks of cancer development. Therefore, blocking WASp signaling and activity can be expected to disrupt these functions in hematopoietic malignancies. To develop such an inhibitor, we first utilized in silico screening with a machine learning platform and identified SMC #13 as a potential inducer of WASp degradation, thereby blocking WASp-dependent cytoskeletal dynamics in hematological cancers.

Since WASp stability highly depends on WIP, it has not been fully purified to date. Thus traditional binding methods such as...
isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR) are not feasible for working with the full length protein, and are challenging for use on fragments. Thus, we determined SMC#13 binding to fluorescently tagged WASp by MST and interferometry analyses.

The differences between the estimated affinity of SMC #13 to WASp and the effective concentration needed for the induction of WASp degradation (Kd of ~30.8 nM relative to 40 µM, respectively) might be explained by the high lipophilicity and moderate solubility of the SMC with a logD~3.3 (Supplementary Fig. 1d) or alternatively due to the strength of WIP; WASp interactions under physiological conditions, which may be disrupted only under higher concentrations of SMC #13.

WASp is exclusively expressed in all hematopoietic lineages, excluding red blood cells. The tissue-specificity of WASp expression makes it an attractive target for hematopoietic cell
targeting, limiting potential off-target effects to bystander non-hematopoietic cells. Torres et al. previously showed that WASp maintains a dynamic equilibrium between its open and closed conformations. When hematopoietic cells are in the resting state (unstimulated), the predominant cellular form of WASp is a closed conformation, which is auto-inhibited by intramolecular interaction between the GBD and the VCA domains. We and others demonstrated that WIP serves as a chaperone of WASp, and this interaction protects WASp from degradation via ubiquitylation and this interaction protects WASp from degradation via others demonstrated that WIP serves as a chaperone of WASp, and their tumors (lower panel) at the end of the experiment. e Number of cells extracted from the tumor. (P = 0.0322, Negative control vs SMC#13) Values are shown as mean ± SEM (DMSO, n = 14; SMC#13, n = 11). The P values were calculated using two-tailed unpaired t-test.

f Kaplan-Meier survival curve of NRG mice transplanted with Raji NHL cells and treated with vehicle (n = 30) or SMC #13 (n = 31). Statistical analysis was performed using log-rank test (P ≤ 0.001).

Contemporary therapeutic approaches mainly focus on upstream receptors or central aberrant signaling pathways. These approaches may be ineffective due to alternative pathways that may lead to primary, acquired, or adaptive resistance in patients, causing relapse. However, the direct degradation of WASp, a key global effector protein, should remain a sensitive target regardless of the mutation profile of a specific lymphatic cancer or patient. The activity of WASp is required to enable cellular functions of the cancer cells, and thus, disrupting WASp function is expected to result in a potent antitumoral effect even in cells without a specific mutation.

To conclude, SMC may serve as a prototypic strategy for targeting WASp and additional hematopoietic-specific cytoskeleton proteins. The demonstrated safety and efficacy of WASp-targeting SMC in vivo, together with the advantages inherent to the strategy of disrupting a key cellular effector protein of lymphatic cancer cells highlights the great promise of this therapy, and the importance of its further development toward clinical studies.

Methods
Reagents. Antibodies were obtained from the indicated suppliers. The following primary antibodies were used for western blotting: mouse anti-GFP 1:500 (Roche Applied Science—Catalogue no. 11 814 460 001), mouse anti-WASp D1 1:250 (sc-5300) and rabbit anti-GAPDH 1:1000 (Santa Cruz—sc-47724). HRP-conjugated goat anti-mouse 1:10,000 (Jackson—11 035 003) was used as a secondary antibody. Proteasome activity was blocked by addition of MG132 (Sigma–Aldrich—C211) at a final concentration of 50 µM for 3 h before the cells were harvested. The following primary antibodies were used for flow cytometry: mouse anti-WASp D1 1:250 (Santa Cruz—sc-5300). The KIM127 hybridoma was purchased from the ATCC (KIM127 (ATCC® CRL2838™)) and the supernatant was purified to obtain the antianitivated human LFA-1 antibody (Sigma–Aldrich). For flow cytometry, secondary Alexa Fluor 488-conjugated goat anti-mouse IgG1 antibody was used (1:2500) (Jackson – A11034). SMC #13 was synthesized and purified (>90% purity) using LC-MS/MS by ChemBridge Research Laboratories LLC.

Protein modeling. A 3D model (PDB ID: 2IFS) of the WHI domain of N-WASP was downloaded from the Protein Data Bank (PDB). Using Discovery Studio 3.0 (BIOVIA) Virtual mutagenesis tool, the model was adapted to the sequence of the WASP WHI domain.

Specifically, the following changes were introduced: V71A; A72V; L74F; R81K (positions relate to the sequence of human WASp).

Additionally, the WIP peptide and a portion the protein linker were deleted from the model.

Candidate library preparation. Two libraries of available drug-like small molecules were obtained from ChemBridge Corporation (San Diego, California, USA) and from the NIH MLSMR in the SDF (structure-data file) format. Using the FAST
algorithm as implemented in Discovery Studio 3.0, from each file, up to ten possible 3D conformations were generated and saved in the PDB format.

**Virtual docking and screening.** Virtual screening was performed using a machine learning classifier trained to distinguish between docking models of experimentally validated protein-small molecules pairs (positive examples) and randomly paired protein and small molecules (negative examples), taken from a curated 3D protein/drug interaction dataset. Docking (including redocking of positive examples) was carried out with the use of PatchDock, with the settings of 'drug' and '4' as the molecule and cluster parameters (respectively). The Random Forest algorithm as implemented in R was used for training the classifier, with the tree number parameter set to 500.

Discovery of WASp-binding candidates was carried out using a set of commercially available small molecules collection NIH’s MLSMR library and from Chembridge Corporation’s CORE Library compound collection. For each small molecule in this set, we performed virtual docking to the modified 2IFS model.
**Fig. 6 SMC #13 inhibits WASp-dependent cellular functions ex vivo in cells obtained from tumors of mice following i.p. administration.** a WASp levels as detected by western blot analysis. Cells obtained from tumors of SMC #13- or control-treated mice were lysed, and WASp expression was analyzed by immunoblot, and normalized to GAPDH as a loading control. Densitometric analysis of the bands was performed with ImageJ. Relative WASp levels were compared to vehicle-treated mice and are presented in the graph below (n = 6, P = 0.0030). Values are shown as mean ± SEM. The p values were calculated using two-tailed paired t-test. b Cell growth analysis as detected by XTT-based proliferation assay of cells extracted from tumors of SMC #13- or vehicle-treated mice (n = 6, P ≤ 0.0001). Values are shown as mean ± SEM. The P values were calculated using two-tailed paired t-test. c Surface staining of the active-LFA-1 on tumor cells of SMC #13- or vehicle-treated mice, as analyzed by FACS (n = 8). d Cells extracted from tumors of SMC #13- or vehicle-treated mice were seeded on a chambered coverslip precoated with ICAM-1. Cell migration was assessed using Zeiss Observer Z1 inverted microscope. Left panel: Cell tracking analysis of five cells from a representative movie of each group. Each line represents the pathway of a single cell. The graph on the right summarizes the mean cell displacement. (Neg Cont.: n = 87; SMC #13: n = 58). (P ≤ 0.0001). Values are shown as mean ± SEM. The P values were calculated using two-tailed unpaired t-test. e Cells extracted from SMC #13- or vehicle-treated mice were incubated overnight over fluorescent gelatin coverslips. Following incubation, cells were fixed, permeabilized and counterstained with phalloidin 594. Images were acquired with a Zeiss Confocal Laser Scanning Microscope (LSM 510 META). The images were analyzed using ImageJ software, and the percentage degradation was determined by the equation: [(degraded area)/(cell area)]×100. (Neg. Cont.: n = 31 cells; SMC #13 n = 46 cells; 3 independent experiments). (P ≤ 0.0001). Values are shown as mean ± SEM. The p values were calculated using two-tailed unpaired t-test. f Tumor sections from SMC #13- or control- treated mice (i.p. injections) were stained with DAPI and with anti-Ki-67 Ab followed by Alexa Fluor 594-conjugated goat anti-rabbit secondary Ab (P ≤ 0.0001), or with g anti-cleaved Caspase-3 Ab followed by Alexa Fluor 594-conjugated goat anti-rabbit secondary Ab. Bright-field and fluorescence images were acquired with a Leica Confocal Laser Scanning Microscope (Leica SP8). (P ≤ 0.0001). Values are shown as mean ± SEM. The p values were calculated using two-tailed unpaired t-test.

**Fig. 7 A suggested model for WASp downregulation by SMC #13.** Following cellular activation, WASp undergoes ubiquitylation on lysine residues 76 and 81, located at the WH1 domain, directing WASp to proteasomal degradation. WIP masks WASp ubiquitylation sites, thereby protecting it from degradation. Upon cellular activation, WASp is released from its auto-inhibitory state and results in a partial dissociation from the C-terminus of WIP at the N-terminal WH1 domain of WASp, while retaining its interaction between the C’ terminus of WASp and the N’terminus of WIP. As a result, WASp is subsequently degraded by the E3 ubiquitin ligases, the Cbls. SMC #13 enhances WASp degradation in activated cells by further interfering with the WIP;WASp interaction, thereby enhancing WASp ubiquitylation.

Then, the results of the PatchDock docking were scored by the trained Random Forest model to predict whether or not the docked models represent pairs that are likely to interact. Then, the small molecules that received the highest score were manually inspected to determine which of them should be purchased for experimental assessment.

**Model redocking and verification.** Forcefield-based optimization was performed for the selected molecules via the Discovery Studio 3.0 ‘Clean Geometry’ tool. Noncovalent bonds between the SMC and the protein were computed with Discovery Studio ‘Monitor’ tool. The resulting putative models were then visually inspected in comparison to the pocket containing ubiquitylation targeted lysine residues 76 and 81 (calculation of the pocket was performed with the use of the ‘Pharmacophore Modelling’ suite in Discovery Studio). Putative models were then inspected for steric clashes between the SMC and the WIP portion of the 2IFS model, using the Discovery Studio ‘Monitor’ tool.

**Cell lines and primary cells.** Blood samples from patients were collected at the Sheba Medical Center with written informed consent in accordance with the declaration of Helsinki, and the study approval by the Bar-Ilan University Ethics Committee. Primary cells, Human Embryonic Kidney (HEK) 293 T cells, Jurkat (clone E6.1) T-ALL and Raji Burkitt’s lymphoma were cultured in RPMI 1640 (Sigma–Aldrich) supplemented with 10% FBS (Biological industries), 2 mM L-glutamine, 50 mg/ml penicillin, 50 mg/ml streptomycin (Sigma–Aldrich). All cells were grown at 37 °C, under an atmosphere containing 5% CO₂.

**Primary PBMC isolation.** Human primary PBMCs were isolated from whole blood of healthy donors or patients, as previously described. Briefly, mononuclear cells were isolated by Ficoll density gradient (Axis Shield—1114547-1) centrifugation. Cells were activated using PMA (Sigma–Aldrich P1585) (2.5 ng/ml) and Ionomycin (Merck Millipore—407950) (1 μg/ml) or left inactivated in the presence or absence of SMC#13 for 24 h.

**WASp knockout cells using CRISPR/CAS9.** CRISPR/CAS9 knockdown of endogenous WASp in T cells was conducted according to published protocol. The pSpCas9(BB)-2A-GFP (PX458) vector was purchased from Addgene, plasmid # 48138. The following RNA guides were designed and subcloned into pSpCas9 (BB)-2A-GFP.

- 5’aacTGCTGGAGATGTAAGTGGATc 3’
- 5’caccATGACTTTACATCAGGAG 3’

**MST measurements.** YFP-tagged WASp, WAVE2-, and N-WASP were purified from cell lysates of HEK 293 T cells, transiently transfected with 10 μg of YFP-WASP, YFP-WAVE2, and N-WASP-YFP by DNA-calcium phosphate co-precipitation. Forty-eight hours post transfection, cells were lysed using ice-cold lysis buffer consisting of 50 mM Tris—HCl (pH 7.6), 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 50 mM NaF, 1% NP-40, and complete protease inhibitor tablets (Roche). MST measurements were performed using the protein purification-free method described by Khavrutskii et al. Briefly, SMC#13 or Y-27632, a ROCKI inhibitor, were diluted to a stock concentration of 400 μM, and serially diluted (200 μM to 1.5 nM) in 200 μL PCR-tubes. Then, the cell lysate was added to the
tubes at a 1:1 volume ratio, and the samples were gently mixed. The samples were incubated at room temperature for 30 min before being loaded into standard-treated glass cover slips (Narishige). After loading into the instrument (Monolith NT.115, NanoTemper), microscale thermophoresis was carried out at 50% blue LED power and 60% MST power. The ratios between normalized initial fluorescence and post temperature-jump fluorescence were calculated and plotted against the concentration of the serially diluted molecule. KD values were determined using the NanoTemper analysis software (MO.Affinity Analysis v2.1.3).

**BLI analysis.** The interaction between the small molecule and the YFP-tagged proteins expressed in HEK 293 cells was determined by biolayer interferometry using the Octet Red 96 instrument (Forte-Bio Inc. Menlo Park, CA). Super Streptavidin biosensor tips were prewetted with PBS to establish a baseline before antibody immobilization. Then biotinylated anti-YFP nanobody (Chromotek GFP-Trap™—gib 250 121150) was immobilized onto Super Streptavidin biosensors and the unbound streptavidin residues were blocked using biocytin (10 μg/mL). Next, the desired YFP-tagged proteins in whole-cell lysates were also immobilized. All the binding data were collected at 30 °C. The association experiments were conducted using cycles of equilibrium (10 min), baseline (1 min), association (2 min), and dissociation (5 min). Binding to SMC #13 was conducted using six different serially diluted concentrations ranging from 50 to 200 μM. The association and dissociation plot and kinetic constants were obtained with Forte-Bio data analysis software. Equilibrium dissociation constants (Kd) were calculated according to the dose-dependent binding response curve.

**Western blot analysis and immunoprecipitation.** For analysis of whole-cell lysates (WCL) or IP experiments, 3 × 10^6 cells or 10 × 10^6 cells were used, respectively. Cells were lysed using ice-cold lysis buffer containing 1% Brij, 1% n-Octyl-b-D-glucoside, 50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 5 mM ethylene-diaminetetraacetic acid (EDTA), 1 mM Na3VO4 and complete protease inhibitor tablets (Roche). Protein samples were resolved with sodium dodeyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membrane, and immunoblotted with appropriate primary antibodies. Protein A/G plus-Agarose beads (Santa Cruz Biotechnology—sc-2003) were used for IP. A precleaving step of cell lysate with protein A/G was performed prior to immunoprecipitation with mouse anti-WASP H-250 (Santa Cruz—sc-6533) antibody.

**Cycloheximide chase assay.** WASp protein stability was determined in the presence or absence of the protein biosynthesis inhibitor, cycloheximide (CA-14126-1). T-ALL cells were incubated with either SMC #13 or vehicle. After 12 h, fresh medium containing cycloheximide (0.1 mg/ml) was added. Cells were lysed at the indicated time points (0, 2, 4, 6, and 8 h).

**FRET analysis.** Fluorescence resonance energy transfer (FRET) efficiency and correction were measured by the donor-sensitized acceptor fluorescence technique. Briefly, three sets of filters were used: one optimized for donor fluorescence (excitation, 458 nm, and emission, 465–510 nm), a second for acceptor fluorescence (excitation, 514 nm, and emission, 530–600 nm), and a third for FRET (excitation, 458 nm; emission, 530–600 nm).

**FRET correction.** FRET correction was performed as described in detail. Briefly, the FRET efficiency (FRETeff) was calculated on a pixel-by-pixel basis as described in detail with the following equation:

\[
\text{FRETeff} = \frac{\text{FRETcorr} \times \text{CFP}}{100},
\]

where FRETcorr is the pixel intensity in the corrected FRET image, and CFP is the intensity of the corresponding pixel in the CFP channel image.

**Gelatin degradation assay.** Glass coverslips (10 mm) were placed in a 24-well plate and precoated with 0.01% Poly-L-lysine (Sigma-Aldrich). The coverslips were then coated with 0.1% Oregon green 488-conjugated gelatin (Invitrogen), cross-linked with 0.5% glutaraldehyde, and coated with 2 μg/ml SDF-1α (PeproTech—RK#48061). Lymphocytes were incubated overnight over the gelatin-coated coverslips. Following incubation, cells were fixed and counterstained with phalloidin 594. Images were acquired with the Zeiss Confocal Laser Scanning Microscope (LSM 510 META) under a ×63 objective lens. The images were analyzed using Imagel software, and the percentage of degradation was determined for each cell according to the equation: %Degradation area = Area of degraded gelatin/Area of corresponding cells × 100.

**Proliferation assay.** Lymphocyte proliferation was assessed with an XTT-based Cell Proliferation Kit (Biological Industries Ltd.) according to the manufacturer's instructions. Briefly, 1 × 10^6 cells were preincubated with the relevant treatment. After 24 h, 100 μl of cell suspension was seeded in triplicate in 96-well microplates and incubated with 0.5 μl XTT substrate; the absorbance of each proliferation product (450 nm) was monitored over time using a microplate plate-reader. Non-specific reference absorption (630 nm) was measured as a control. Proliferation was calculated by the differences of cell number 24 h after treatment relative to the control.

**Toxicity assay.** Healthy donor PBMCs (1 × 10^6 cells/ml) were incubated for 24 h with different concentrations of SMC #13 ranging from 18.75-600 μM in the presence of 1.25% DMSO at each concentration and in the negative control. Toxicity was evaluated using Propidium iodide (PI) staining. For PI staining, after incubation with SMC #13, cells were centrifuged for 7 min at 400 × g and resuspended in 500 μl staining buffer containing PI (0.5 μg/ml), followed by flow cytometry analysis using a FACS® Aria® III (BD Biosciences) cell analyzer.

**Lymphocyte migration assay.** Migration assay was performed using 1 × 10^5 cells seeded over chambered cover slips (LabTek) precoated with 6 μg/ml ICAM-1-Fc (BioLegend) and 2 μg/ml SDF-1α (Reproclone) suspended in 20 mM Tris pH 9, 139 mM NaCl, and 2 mM MgCl2 at 4 °C, overnight. The chambered coverslips were preincubated with imaging buffer containing 10% FCS for blocking. Cells were incubated at 37 °C, 5% CO2, 5% O2 until they allow them settle before imaging. The DIC images were acquired with the Zeiss Observer Z1 inverted microscope every 5 sec for 20 min under an ×20 objective lens using Zen software. The random displacement of the cells was automatically tracked and analyzed using the ImageJ software TrackMate plugin. All the movies were taken using the same settings. An individual trace was assigned to each of the analyzed cells. One representative field out of 6 random fields is presented. Playback speed is fifteen frames per sec.

**Flow cytometry analysis**

**Extracellular staining.** Lymphocytes (3 × 10^6) were stained with 1 μg/ml anti–human LFA-1 antibody (purified from KIM127 hybridoma sup) for 30 min at 37 °C, followed by staining with Alexa Fluor 488-conjugated goat anti-mouse IgG1 secondary antibody (Jackson), 30 min on ice.

**Intracellular staining.** Cells (1 × 10^6) were either stimulated with 2.5 ng/ml PMA and 1 μg/ml ionomycin or left unstimulated. Cells were collected (5 × 10^5 cells per sample), washed twice with PBS, and fixed with 0.4 ml 3.7% paraformaldehyde for 20 min at room temperature. After two additional washes, cells were permeabilized with 0.1% Triton X-100 in PBS for 4 min at room temperature. Cells were blocked for 45 min with 2% goat serum, followed by 45 min incubation with 0.1 μg mouse anti-WASp Ab, on ice. The samples were washed twice, and then incubated with 1:2000-diluted Alexa Fluor 488-conjugated goat anti-mouse IgG1 antibody (Jackson), for 45 min on ice. Fluorescence was analyzed by flow cytometry on a FACSAria™ cell analyzer.

**Cytokine release assay.** Freshly isolated PBMCs from healthy donors (1 × 10^6 cells/ml) were incubated for 24 h with either vehicle only (DMSO) as control, 40 μM of SMC #13, or left untreated. For positive control, cells were incubated with 7 μg/ml PHA for 96 h. After incubation, the supernatant from each sample was collected. The levels of human cytokines, IL-6, IL-10, TNF-α, and IFN-γ were determined using Human Mini ELISA Development kits (PeproTech).

**Scratch-wound assay.** Melanoma cells (MEL1106) were seeded at a concentration of 1 × 10^6 cells/well per well over culture-insert-four-well in μ-Dish 35 mm (Ibidi®) with a silicon insert to create 500 μm cell free gaps. Once cells reached high confluency, they were treated with SMC #13 for 24 h or vehicle only as a negative control. For a positive control, cells were treated for 10 minutes with 0.5 μM cytochalasin D, which inhibits actin-dependent cell migration. To follow wound colonization which reflects a combination of both cell proliferation and cell migration over time, images were taken every 30 min for a total of 18 h of incubation at 37 °C with 5% CO2. Five fields were captured in every experiment using DMi8 Leica wide-field inverted microscope (Leica Microsystems, Mannheim, Germany), equipped with an incubation chamber and sCMOS DFC900GT Leica camera, and driven by LaX software, using a 1 × 1.4NA objective. The migratory capability was quantified using the ImageJ plug-in "Wound healing size tool," which allows quantification of the wound area, wound coverage of the total area, and average wound width.

**Mice.** SCID/NOD mice were purchased from the Jackson Labs. All mice used were from colonies that were inbred and maintained under SPF conditions at the Bar-llan animal house. Housing and breeding of mice and experimental procedures were done according to the Bar-Ilan University Ethics Committee guidelines (IRB: 82-10-18), and mice were euthanized using CO2. For in vivo efficacy studies, 6-8-week-old male SCID/NOD mice were used. Mice were subcutaneously injected with 3 × 10^6 human Raji B-NHL cells, in PBS mixed with Matrigel (CORNING) (1:1 v/v ratio). Tumor size was measured daily using a digital caliper, and the following formula was used to calculate the tumor volume, Volume = 0.5 × (major axis) × (minor axis)^2. When the tumors reached 100 mm^3, mice were randomly divided into two groups, and were treated intratumorally (i.t.) or intraperitoneally (i.p.). Tumor burdens of the treated mice with 20 mg/kg of SMC #13 were suspended in Tyrode’s isotonic buffer with 20% cyclodextrin (i.t.), or 100 mg/kg SMC #13 dissolved in DMSO, or with vehicle (i.p.).
Pharmacokinetics

Pharmacokinetic studies were conducted to evaluate the clearance of the anti-CD25 therapy. Tumor tissues were then rinsed twice in PBS and once in PBS with 0.1% TWEEN, rinsed twice in PBS and once in PBS with 0.1% TWEEN, followed by incubation for 10 min. The tubes were centrifuged at 2000 × g for 10 min. The supernatant was transferred to centrifuge tubes containing 7.5 U heparin. Plasma was separated by centrifugation at 2000 × g and the supernatant was transferred and stored at −80 °C. Tissues were frozen under liquid nitrogen and stored at −80 °C. All samples were supplemented with 0.1 M NaOH, and the samples were vortexed for 2 min. The tubes were centrifuged at 2000 × g for 10 min. The resulting organic layer was separated and evaporated using Savant Speed Vac SC110A Concentrator Centrifuge.

HPLC protocol

The concentration of SMC #13 was measured using Hitachi Elite LaChrom HPLC System on a Hypersil GOLD 5 µm column (250 mm ID × 2.1 mm OD). The mobile phase consisted of a two buffer gradient system (Buffer A: H2O:ACN:TFA 95:5:0.1; Buffer B: H2O:ACN:TFA 19:90:0.1). Samples were reconstituted in a volume of Buffer B equal to that of the original sample, without trifluoroacetic acid (TFA). Samples were loaded with an injection volume of 10 µl, and analyzed using the following linear gradient: 0–18 min—100% Buffer B, 19–25 min—30% Buffer B, 18–19 min—100% Buffer B, 19–25 min—30% Buffer B at a flow rate of 0.5 ml/min for the PK and 0.35 ml/min for the PPB with a temperature of 30 °C. SMC #13 was detected at 270 nm with a retention time of 9.3 and 13 min (respectively to the flow rate) using spike and quantity estimated from the calibration curve of standards prepared at 100, 25, 6.25, 1.56, and 0.39 µM.

Statistical analyses

Data calculations were conducted in Microsoft Excel while data were graphed and statistical analysis was performed using Prism (GraphPad, v9). P values were calculated using a two-tailed paired or unpaired t-test. Where >2 conditions were compared, a one-way ANOVA with a Tukey post-hoc test or Dunnnet’s multiple comparison was used to calculate P values. In all cases, the threshold P value required for significance was 0.05. Survival analysis was performed using log-rank test by R software.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All experimental data regarding the in vitro and in vivo systems and specific binding of SMC #13 are provided in the text and in the source data file. Source data are provided with this paper.

Received: 16 March 2020; Accepted: 3 September 2021;
Published online: 22 September 2021

References

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
2. Harris, N. L. et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann. Oncol. 10, 1419–32 (1999).
3. Ottensmeier, C. The classification of lymphomas and leukemias. Chem. Biol. Interact. 135–136, 653–64 (2001).
4. Armitage, I. O. Staging non-Hodgkin lymphoma. CA Cancer J. Clin. 55, 568–76 (2005).
5. Baron, F. & Storb, R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin. Immunopathol. 26, 71–94 (2004).
6. Loos, R. L., Leventhal, H., Pappo, A. S., D. V. & Nerenz, D. R. Side effects and emotional distress during cancer chemotherapy. Cancer 63, 604–612 (1989).
7. Sharma, P., Ma-I Lieskovsk, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
8. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372, 311–319 (2015).
9. Mervyn, R. W., Anand, P., Wright, K. T. & Rodig, S. J. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 1, 2643–2654 (2017).
10. Ansell, S. et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood 128, 183–183 (2016).
11. Armand, P. et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia https://doi.org/10.1038/s41375-020-0939-1 (2020).
12. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 373, 1507–1517 (2014).
13. Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell malignancies. N. Engl. J. Med. 377, 2545–2554 (2017).
14. Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
15. Izzedine, H. et al. Renal effects of immune checkpoint inhibitors. Nephrol. Dial. Transplant. 32, 936–942 (2017).
16. Bonifant, C. L., Jackson, H. J., Brentjens, R. J. & Curran, K. J. Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncol. 3, 1601 (2016).
17. Lieber, M. R. Mechanisms of human lymphoid chromosomal translocations. Nat. Rev. Cancer 16, 387–398 (2016).
18. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 668–74 (2011).
19. Yamazaki, D., Kurisu, S. & Takenawa, T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 96, 379–386 (2005).
20. Yamaguchi, H. & Condeelis, J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim. Biophys. Acta 1773, 642–652 (2007).
21. Hall, A. The cytoskeleton and cancer. Cancer Metastasis Rev. 28, 5–14 (2009).
22. Bargou, R. C. et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87, 4340–7 (1996).
23. Nagel, D., Vincendeau, M., Ettebuher, A. C. & Krappmann, D. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Oncogene 33, 5655–5665 (2014).
24. Grywalska, E. et al. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease. Adv. Clin. Exp. Med. https://doi.org/10.17219/acem/74437 (2014).
25. Olson, M. F. & Sahai, E. The actin cytoskeleton in cancer cell motility. Clin. Exp. Metastasis 26, 273–87 (2009).
26. Nürnberg, A., Kitzing, T. & Grosse, R. Nucleating actin invasion. Nat. Rev. Cancer 11, 117–187 (2011).
27. Konno, A., Kirby, M., Anderson, S. A., Schwartzberg, P. L. & Candotti, F. The expression of Wiskott-Aldrich syndrome protein (WASP) is dependent on WASP-interacting protein (WIP). Int. Immunol. 19, 185–92 (2007).
28. Thrasher, A. J. & Burns, S. Wiskott-Aldrich syndrome: a disorder of haematopoietic cytoskeletal regulation. Microsc. Res. Tech. 47, 107–113 (1999).
29. Imai, K. et al. Clinical course of patients with WASP gene mutations. Blood 103, 456–64 (2004).
30. Moulding, D. A., Record, J., Malinova, D. & Thrasher, A. J. Actin cytoskeletal defects in immunodeficiency. Immunol. Rev. 256, 282–99 (2013).
31. Al-Hassad, M. J., Ramesh, N. & Geha, R. S. Wiskott-Aldrich syndrome: a comprehensive review. Ann. N. Y. Acad. Sci. 1285, 26–43 (2013).
32. Andreansky, S. et al. WASP- mice exhibit defective immune responses to influenza A virus, Streptococcus pneumoniae, and Mycobacterium bovis BCG. Exp. Hematol. 33, 443–451 (2005).
33. Bouma, G., Burns, S. O. & Thrasher, A. J. Wiskott-Aldrich syndrome: immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology 214, 778–90 (2009).
34. Bouma, G., Burns, S. & Thrasher, A. J. Impaired T-cell priming in vivo resulting from dysfunction of WASP-deficient dendritic cells. Blood 110, 4278–4284 (2007).
35. Weinger, L. S. et al. Wiskott-Aldrich syndrome protein (WASP) and N-WASP are critical for peripheral B-cell development and function. Blood 119, 3966–74 (2012).
36. Tang, Z., Arasay, L. M. & Fatallah-Shaykh, H. M. c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced red blood cell aggregation in glycosylated erythrocytes. PloS ONE 9, e87266 (2014).
37. Desmarais, V. et al. N-WASP and cortactin are involved in invadopodium-dependent chemotaxis to EGF in breast tumor cells. Cell Motil. Cytoskeleton 66, 303–316 (2009).
38. Sarmiento, C. et al. WASP family members and formin proteins coordinate regulation of cell protrusions in carcinoma cells. J. Cell Biol. 180, 1245–1260 (2008).
39. Kurisu, S., Suetugu, S., Yamazaki, D., Yamaguchi, H. & Takenawa, T. Rac-WAVE signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells. Oncogene 24, 1309–1319 (2005).
40. Reicher, B. et al. Ubiquitination-dependent negative regulation of WASP is essential for actin cytoskeleton dynamics. Mol. Cell. Biol. 32, 3135–3163 (2012).
41. Fried, S. et al. Triple-color FRET analysis reveals conformational changes in the WIP-WASp actin-regulating complex. Sci. Signal. 7, 331, ra60 (2014).
42. Reicher, B. et al. WASP and WAVE proteins: from structure, through function, to clinical aspects. J. Clin. Cell. Immunol. 01, S12–17 (2013).
43. Joseph, N. et al. A conformational change within the WAVE2 complex is required for its interaction with N-WASP. J. Biol. Chem. 282, 8446–8453 (2007).
44. Hou, T., Li, Y. & Wang, W. Prediction of peptides binding to the PKA RIIalpha subunit using a hierarchical strategy. Bioinformatics 27, 1814–21 (2011).
45. Peterson, F. et al. Multiple WAVE-1 interacting protein recognition motifs are required for a functional interaction with N-WASP. J. Biol. Chem. 282, 1309–9 (2007).
46. Barda-Saad, M. et al. Cooperative interactions at the SLP-76 complex are necessary for efficient IgG-mediated phagocytosis. Blood 95, 2943–6 (2000).
47. Astrakhann, A., Ochs, H. D. & Rawlings, D. J. Wiskott-Aldrich syndrome protein is required for homeostasis and function of invariable NKT cells. J. Immunol. 182, 7370–80 (2009).
48. Kirchmair, J., Laggner, C., Wolber, G. & Langer, T. Comparative analysis of protein-bound ligand conformations with respect to catalyst space subsampling algorithms. J. Chem. Inf. Model. 52, 3328–3341 (2012).
49. Lafouresse, F. et al. Wiskott-Aldrich syndrome protein controls antigen-presenting cell-driven CD8+ T-cell motility by regulating adhesion to intercellular molecule-1. Immunity 137, 183–196 (2012).
50. Raj, R. et al. Antigen-receptor-induced activation and cytokinetic rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J. Exp. Med. 190, 1329–42 (1999).
51. Gallego, M. D., Santamaría, M., Peña, J. & Molina, I. J. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood 90, 3089–97 (1997).
52. Westerberg, L. et al. Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood 105, 1144–1152 (2005).
53. Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Nucleic Acids Res. 33, W363–7 (2005).
54. Abd El Meguid, S. et al. Human Neutrophil protein binding domains: a novel database of cell binding domains. Sci. Rep. 7, 44863 (2017).
55. Bosticard, M., Marangoni, F., Aiuti, A., Villa, A. & Grazia Roncarolo, M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 113, 6288–95 (2009).
56. Matalon, O. et al. Actin retrograde flow controls natural killer cell response by regulating the conformation state of SHP-1. EMBO J. 37, e96264 (2018).
57. Shembade, N. et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 9, 254–262 (2008).
58. Molina, I. J., Sancho, J., Terhorst, C., Rosen, F. S. & Remold-O’Donnell, E. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J. Immunol. 151, 4383–90 (1993).
59. Zhang, H. et al. Impaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils. Immunity 25, 285–295 (2006).
60. Ishiihara, D., Dovas, A., Park, H., Isaac, B. M. & Cox, D. The chemotactic defect in Wiskott-Aldrich syndrome macrophages is due to the reduced persistence of directional protrusions. PLoS ONE 7, e9119–1–2 (2012).
61. Lomire, R., Buckel, P. M., Katz, D. R., Kinnon, C. & Thrasher, A. J. Wiskott-Aldrich syndrome protein is necessary for efficient IgG-mediated phagocytosis. Blood 95, 2943–6 (2000).
62. Voss, H. & Nussinov, R. The ins and outs of leukocyte integrin signaling. J. Med. Chem. 51, 9841–59 (2008).
63. Abram, C. L. & Lowell, C. A. The ins and outs of leukocyte integrin signaling. Trends Cell Biol. 18, 253–61 (2008).
64. Kurisu, S., Suetugu, S., Yamazaki, D., Yamaguchi, H. & Takenawa, T. Rac-WAVE2 signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells. Oncogene 24, 1309–1319 (2005).
65. Matalon, O. et al. Actin retrograde flow controls natural killer cell response by regulating the conformation state of SHP-1. EMBO J. 37, e96264 (2018).
91. Chaudhry, M. S., Velardi, E., Malard, F. & Brink, M. R. M. Van Den. Immune reconstitution after allogeneic hematopoietic stem cell transplantation: time to T up the thymus. J. Immunol. https://doi.org/10.4049/jimmunol.1901100 (2017)

92. Kang, D.-H. et al. Significant impairment in immune recovery after cancer treatment. Nurs. Res. 58, 105–14 (2009).

93. Gómez, H. et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysis. J. Clin. Oncol. 16, 2852–57 (1998).

94. Bajwa, R. et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J. Clin. Med. Res. 11, 225–236 (2019).

95. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–54 (2012).

96. Hansel, T. J. W. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin. Hematol. 46, 289–312 (2009).

97. Luan, Q., Zelter, A., MacCoss, M. J., Davis, T. N. & Nolen, B. J. Identification of Wiskott-Aldrich syndrome protein (WASP) binding sites on the branched actin filament nucleator Arp2/3 complex. Proc. Natl. Acad. Sci. USA https://doi.org/10.1073/pnas.1716622115 (2018).

98. Kunte, I. D. Structure-based strategies for drug design and discovery. Science 257, 1078–82 (1992).

99. Kubiniy, H. Nonlinear dependence of biological activity on hydrophobic character: the bilinear model. Farm. Sci. 34, 248–276 (1979).

100. Stewart, D. M. et al. Studies of the expression of the Wiskott-Aldrich syndrome protein. J. Clin. Invest. 97, 2627–34 (1996).

101. Torres, E. & Rosen, M. K. Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP. J. Biol. Chem. 281, 3513–3520 (2006).

102. Fried, S., Matalon, O., Noy, E. & Barda-Saad, M. WIP: more than a WASp-interacting protein. J. Leukoc. Biol. 96, 713–727 (2014).

103. Noy, E., Fried, S., Matalon, O. & Barda-Saad, M. WIP remodeling actin behind the scenes: how WIP reshapes immune and other functions. Int. J. Mol. Sci. 13, 7629–47 (2012).

104. Steward, D. M., Tian, L. & Nelson, D. L. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP-interacting protein. Oncogene 162, 5019–5024 (1999).

105. Davies, M. A. & Samuels, Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 29, 5545–5555 (2010).

106. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–9 (1989).

107. Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).

108. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–3 (2005).

109. Voena, C. & Chiarle, R. RHO family GTPases in the biology of lymphoma. Cells 8, 646 (2019).

110. Murga-Zamalloa, C. A. et al. NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma. Oncogene 36, 2085–2094 (2017).

111. Chandrashekar, D. S. et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649–658 (2017).

112. BERNSTEIN, F. C. et al. The Protein Data Bank. A computer-based archival system for macromolecular structures. Exs. J. Biochem. 80, 319–324 (1977).

113. Bern, L. et al. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput. Biol. 6, e1000976 (2010).

114. Ho, T. K. Random decision forests. In Proceedings of 3rd International Conference on Document Analysis and Recognition, vol. 1, 278–282 (IEEE Comput. Soc. Press, 1995).

115. Law, A. & Wiener, M. Classification and Regression by Random Forest. R News 2, 18–22 (2002).

116. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).

117. Suarez-Arnedo, A. et al. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS ONE 15, e0232565 (2020).

Acknowledgements
We thank Matan Y. Avivi, Anat Raiff, and Dr. Alex Vorvak for their technical assistance, Dr. Lisette Bronswijk-Deddens (Sartorius) for her help with the BLI data analysis and Prof. Bilha Fischer for her advice on the chemical characterization of the SMC. This research was funded in part by the Israel Science Foundation (grant no. 491/10), and in part by the Israel Innovation Authority.

Author contributions
M.B.S., G.B. and N.J. designed the research. G.B., A.B.S., E.N., N.J., A.P., N.R., O.L., L.I., A.F., Y.O. and S.F. performed the experiments. M.K. and A.A. provided the blood samples of the patients with informed consent in accordance with the declaration of Helsinki (0196-13-HMO) and approval of Bar-Ilan University ethics committee, and Sheba medical center. G.B., A.B.S., E.N., N.J., A.P. and M.B.S. analyzed the data. M.B.S. wrote the manuscript.

Competing interests
"WASP-protecting small molecules, compositions, methods and uses thereof in the treatment of innate and acquired immune-related disorders or conditions” PCT/IB2014/061907, patent author: M.B.S. The remaining authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-25842-7.

Correspondence and requests for materials should be addressed to Mira Barda-Saad.

Peer review information Nature Communications thanks Daniel Thomas and the other anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021